A Real-World Study of Ipilimumab Treatment After Nivolumab Treatment in Melanoma in Japan
Sponsor: Bristol-Myers Squibb
Listed as NCT03165422, this observational or N/A phase trial focuses on Melanoma and remains completed. Sponsored by Bristol-Myers Squibb, it has been updated 10 times since 2017, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
10 versions recorded-
Sep 2024 — Present [monthly]
Completed
-
Jul 2024 — Sep 2024 [monthly]
Completed
-
Jan 2021 — Jul 2024 [monthly]
Completed
-
Nov 2019 — Jan 2021 [monthly]
Completed
Status: Active Not Recruiting → Completed
-
Nov 2018 — Nov 2019 [monthly]
Active Not Recruiting
Status: Completed → Active Not Recruiting
▶ Show 5 earlier versions
-
Jun 2018 — Nov 2018 [monthly]
Completed
-
Apr 2018 — Jun 2018 [monthly]
Completed
Phase: NA → None
-
Mar 2018 — Apr 2018 [monthly]
Completed NA
Status: Recruiting → Completed
-
Aug 2017 — Mar 2018 [monthly]
Recruiting NA
Status: Not Yet Recruiting → Recruiting
-
Jun 2017 — Aug 2017 [monthly]
Not Yet Recruiting NA
First recorded
Mar 2017
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Bristol-Myers Squibb
- Ono Pharmaceutical Co. Ltd
For direct contact, visit the study record on ClinicalTrials.gov .